Diseases & Disorders
(G193)
IRS Verified
DX Registered
990 on File
FIBROLAMELLAR CANCER FOUNDATION
Financial strength (30%)
94/100
Reliability (20%)
50/100
Effectiveness (25%)
78/100
Impact (25%)
No data yet
CharityAI™ Score
Not yet evaluated
Mission Statement
FCF's mission is three-fold: 1. Find a cure and treatment options 2. Raise awareness of this disease 3. Connect and support the fibrolamellar community of patients and their families
Financial Overview — FY 2024
$3.4M
Total Revenue
$2.9M
Total Expenses
$6.9M
Net Assets
4
Employees
Revenue Sources
Expense Breakdown
Program Expense Ratio
82.0%
Fundraising Efficiency
11.0%
Operating Reserve
29.11x
Liability-to-Asset
32.3%
Revenue Diversification
90.5%
Executive Compensation
$251K
Compared with Peers
FY 2024
Compared with 638 similar organizations
(United States, Diseases & Disorders, $1M–$10M in expenses), FY 2024.
This organization
Middle half of peers (P25–P75)
Peer median
| Ratio | This org | Peer median | Position (P10 → P90) | |
|---|---|---|---|---|
|
Program expense ratio
Program expenses / total expenses
· higher is better
|
82.0% | 82.3% |
P10P90
|
Below median |
|
Admin expense ratio
Management and general / total expenses
· lower is better
|
17.0% | 11.5% |
P10P90
|
Below median |
|
Fundraising expense ratio
Fundraising expenses / total expenses
· lower is better
|
1.0% | 2.8% |
P10P90
|
Above median |
|
Fundraising efficiency
Fundraising expenses / gross fundraising income
· lower is better
|
11.0% | 110.9% |
P10P90
|
Top quarter |
|
Operating reserve
Months of expenses covered by net assets
· higher is better
|
29.1 mo | 11.4 mo |
P10P90
|
Top quarter |
|
Liabilities to assets
Total liabilities / total assets
· lower is better
|
32.3% | 12.7% |
P10P90
|
Below median |
|
Revenue concentration
Share of revenue from the largest source
· lower is better
|
90.5% | 91.5% |
P10P90
|
Above median |
|
Revenue growth
Year over year revenue growth
|
15.3% | 9.6% |
P10P90
|
|
|
Expense growth
Year over year expense growth
|
-48.0% | 8.8% |
P10P90
|
|
|
Surplus margin
Surplus as a share of revenue
|
16.4% | 2.2% |
P10P90
|
Financial History
| Year | Revenue | Expenses | Net Assets | Program % | Staff |
|---|---|---|---|---|---|
| 2024 | $3.4M | $2.9M | $6.9M | 82.0% | 4 |
| 2023 | $3.0M | $5.5M | $6.4M | 91.8% | 5 |
| 2022 | $6.1M | $2.6M | $9.3M | 84.2% | 3 |
| 2021 | $4.0M | $1.9M | N/A | — | 3 |
Donor Reviews
Write a ReviewNo reviews yet
Be the first to share your experience with this organization.